The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis07 May 2010 • by Natalie Aster
“The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis”, a report from GBI Research, is an essential source of data and analysis on the cancer market in the top 7 markets of the world. It covers the market landscape, key market trends, market drivers and restraints. The report also identifies key treatment usage patterns across 7 major markets namely, the US, EU5 and Japan. In addition, it brings out the existing competitive landscape of the oncology therapeutics market, characteristics of the top five market indicators, and mergers and acquisitions that have taken place involving cancer therapies over the last one year.
The Global Oncology Therapeutics Market is Forecast to Grow at More Than the Overall Pharmaceutical Industry Growth Rate
The global oncology therapeutics market was valued at $48.1 billion in 2008. The growth in the market is primarily driven by the rapid uptake of target therapies and new developments that have come to treat the niche segments such as renal cell carcinoma, liver cancer and stomach cancers with high unmet needs. However, the growth of the market is expected to slow down marginally due to the influx of many “me too” versions of established therapies. In spite of this, the global cancer therapeutics market is expected to grow at a Compound Annual Growth Rate (CAGR) of 10.9% between 2008 and 2015.
The US, with an Approximate Market Share of 55.1% in 2008, was the Leading Market in the Global Cancer Therapeutics market
In 2008, the oncology therapeutics market in the US was estimated at approximately $26.5 billion, indicating a CAGR of 16.3% between 2000 and 2008. However, in anticipation of new healthcare regulations, the market is expected to slow down to 11% between 2008 and 2015 and record sales value of $55.1 billion by 2015. Similarly, in 2008, the oncology therapeutics market in the EU5 countries was estimated at approximately $15.5 billion, indicating a CAGR of 15.7% between 2000 and 2008. Oncology therapeutics market in Japan was estimated at approximately $6.1 billion, indicating a CAGR of 15.6% between 2000 and 2008.
Breast Cancer Therapeutic Indication was the Leading Therapy Market with an Estimated Market Share of 16% of the Global Oncology Therapeutics Market
In 2008, the top five cancer therapeutic indications accounted for approximately 58.1% of the global oncology therapeutics market. Breast cancer was the leading therapeutic indication with an estimated market share of 16.5%, followed by Non-Hodgkin’s lymphoma (NHL) and colorectal cancer (CRC) which accounted for an approximate market share of 12.8% and 11.4%, respectively. Prostate cancer therapeutics market, with an estimated market share of 10.5%, was the next leading therapeutic indicator, followed by lung cancer.
Roche/Genentech, Novartis and Sanofi-Aventis are the Top Three Players Operating in the Global Oncology Market
In 2008, the top ten companies in the oncology therapeutics market accounted for 82.3% of the global oncology therapeutics market. Rituxan was the leading cancer therapy brand with an approximate sales value of $5.5 billion, followed by Avastin, which recorded sales of $4.8 billion and Herceptin, which registered net sales worth $4.7 billion. The top three companies namely, Roche/Genentech, Novartis and Sanofi-Aventis, accounted for approximately 50% of the global oncology therapeutics market in 2008.
About GBI Research
GBI Research is a leading business information company providing global business information reports and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.